Quantbot Technologies LP and Charles Schwab Investment Management Inc. have increased their holdings in Charles River Laboratories International (CRL), while the Manufacturers Life Insurance Company, FORA Capital LLC, and Mudita Advisors LLP have reduced their positions. CRL has announced its third-quarter 2024 results outperforming revenue expectations but with weak earning per share. Despite this, the company has raised its annual profit forecast due to stabilizing biotech demand. The company is set to present at UBS and Jefferies Conferences where it's likely to discuss strategic updates. CRL's shares have been downgraded to 'Underperform' by CLSA following a more cautious funding environment and lowered expectations on its results. The Massachusetts-based labs plan to cut 1,300 workers and shut down over a dozen sites, stirring mixed reactions in the market. CRL has also entered strategic collaborations with CEBINA and Autobahn Labs aimed at accelerating cutting-edge neuroscience research. Further reduction in the company's shares has been seen from several entities including Entropy Technologies LP and Victory Capital Management Inc.
Charles River Laboratories International CRL News Analytics from Wed, 27 Mar 2024 07:00:00 GMT to Sat, 30 Nov 2024 09:45:27 GMT -
Rating -2
- Innovation 0
- Information 8
- Rumor -5
